Latest Articles
Nivolumab Plus Ipilimumab in Advanced Ovarian and Endometrial Clear Cell Cancers - The ASCO Post
Nivolumab Plus Ipilimumab in Advanced Ovarian and Endometrial Clear Cell Cancers The ASCO Post
Published: Aug. 6, 2025, 3:38 p.m.
Modern Gynecology – Challenges, Problems, Prospects: Interview with Doctor of Medical Sciences Volodymyr Terekhov - Open4business.com.ua.
Modern Gynecology – Challenges, Problems, Prospects: Interview with Doctor of Medical Sciences Volodymyr Terekhov Open4business.com.ua.
Published: Aug. 6, 2025, 3:15 p.m.
Real-World Study on Adverse Drug Reactions of Pembrolizumab in Endometrial Cancer Treatment: Insights from the FAERS Database - Frontiers
Real-World Study on Adverse Drug Reactions of Pembrolizumab in Endometrial Cancer Treatment: Insights from the FAERS Database Frontiers
Published: Aug. 6, 2025, 2:27 p.m.
Gates Foundation to Spend $2.5 Billion on Women’s Health by 2030 - U.S. News & World Report
Gates Foundation to Spend $2.5 Billion on Women’s Health by 2030 U.S. News & World Report
Published: Aug. 6, 2025, 1:40 p.m.
Mother with stage four endometriosis launches petition to raise awareness of ‘painful’ condition in schools - Northampton Chronicle and Echo
Mother with stage four endometriosis launches petition to raise awareness of ‘painful’ condition in schools Northampton Chronicle and Echo
Published: Aug. 6, 2025, 1:37 p.m.
NICE approves first immunotherapy combination for endometrial cancer - Wired Gov
NICE approves first immunotherapy combination for endometrial cancer Wired Gov
Published: Aug. 6, 2025, 1:13 p.m.
Shell Q2 Earnings Beat Even as Production & Oil Prices Fall - The Globe and Mail
Shell Q2 Earnings Beat Even as Production & Oil Prices Fall The Globe and Mail
Published: Aug. 6, 2025, 1:12 p.m.
Endometriosis Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie/Neurocrine Biosciences - The Globe and Mail
Endometriosis Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie/Neurocrine Biosciences The Globe and Mail
Published: Aug. 6, 2025, 1:11 p.m.
AIM ImmunoTech’s Oncology Drug Ampligen to Be Featured in - GlobeNewswire
AIM ImmunoTech’s Oncology Drug Ampligen to Be Featured in GlobeNewswire
Published: Aug. 6, 2025, 1:03 p.m.
CSX Executive Vice President and Chief Commercial Officer to Address Deutsche Bank’s 2025 Transportation Conference - The Globe and Mail
CSX Executive Vice President and Chief Commercial Officer to Address Deutsche Bank’s 2025 Transportation Conference The Globe and Mail
Published: Aug. 6, 2025, 1 p.m.
Link copied to clipboard!